Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ: ARGX )

581.21 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
The company says it's still running additional testing of the drug, calling the results "positive." 
Via Investor's Business Daily
Breaking Down argenx: 12 Analysts Share Their Views
Via Benzinga
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024
ARGX stock results show that argenx missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
The Analyst Verdict: argenx In The Eyes Of 12 Experts
Via Benzinga
Key Takeaways From argenx Analyst Ratings
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
argenx to Present at BofA Securities 2024 Health Care Conference
From argenx SE
Via GlobeNewswire
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
From argenx SE
Via GlobeNewswire
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
From argenx SE
Via GlobeNewswire
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current... 
Via Benzinga
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
From argenx SE
Via GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
From argenx SE
Via GlobeNewswire
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart... 
Via Benzinga
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. 
Via Benzinga
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of Micron Technology, Inc. (NASDAQ: MU) rose sharply in today’s pre-market trading as the company reported upbeat results for its second quarter and issued 
Via Benzinga
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
From argenx SE
Via GlobeNewswire
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.